News

  • CROSSJECT receives €2.9M from Bpifrance as part of the PIAVE financing

    This milestone payment is part of the PIAVE financing, amounting to a total of €6.7M and announced in November 2015. 

    Read the Press Release

    Read more
  • CROSSJECT receives authorization to conduct Zeneo® Midazolam bioequivalence study

    - Major milestone for the payment of the second tranche (€ 2.8M) of Bpifrance’s PIAVE financing to CROSSJECT
    - Significant competitive edge of Zeneo® in intramuscular injection on subjects having an epileptic seizure 

    Read the Press Release

    Read more

Events

  • 01/01/2017

    Copenhagen European Midcap Event

    Meet us in Copenhagen, Mai 18th 2017, during the European Midcap Event.

    Read more
  • 01/01/2017

    Large and Midcap Event 2017

    Crossject will meet institutional investors on the occasion of Large and Midcap Event in Paris, October 5 and 6, 2017.

    Read more

video

Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos